Trial Profile
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 31 May 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 31 May 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jun 2024.
- 03 May 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Aug 2023.